A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T

NCT00395863 Phase 4 COMPLETED Results posted

Compare the efficacy of MultiHance and Magnevist

Details

Lead sponsor	Bracco Diagnostics, Inc
Phase	Phase 4
Status	COMPLETED
Enrolment	46
Start date	2006-11
Completion	2008-03

Conditions

• Brain Tumor

Interventions

• Multihance
• Arm 2 - Magnevist

Primary outcomes

• Global Diagnostic Preference Between the Two Exams — Postdose Images for MultiHance Exam and for Magnevist Exam Compared
  Assessed by 3 blinded Readers for each of the 41 patients who had both MultiHance and Magnevist post dose MRI exam to assess whether the image with MultiHance was preferred, both contrast agents were equal, or the image with Magnevist was preferred. Each patient's image was reviewed by 3 readers.

Countries

United States